Rexahn Pharmaceuticals, Inc. Announces $5.7 Million Registered Direct Offering

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (the “Company”) (NYSE MKT: RNN) today announced that it has received commitments from a single healthcare dedicated institutional investor to purchase an aggregate of approximately $5.7 million of the Company’s common stock.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC